A G Hirsch1, W F Stewart2, A S Sundaresan1, A J Young3, T L Kennedy4, J Scott Greene4, W Feng3, B K Tan5,6, R P Schleimer5,6, R C Kern5,6, A Lidder7, B S Schwartz1,8. 1. Department of Epidemiology and Health Services Research, Geisinger Health System, Danville, PA, USA. 2. Research Development and Dissemination, Sutter Health, San Francisco, CA, USA. 3. Department of Biomedical and Translational Informatics, Geisinger Health System, Danville, PA, USA. 4. Department of Otolaryngology/Head and Neck/Facial Plastic Surgery, Geisinger Health System, Danville, PA, USA. 5. Department of Otolaryngology Head and Neck Surgery Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 6. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, USA. 8. Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MA, USA.
Abstract
BACKGROUND: The objective of this study was to describe the first US-based study to use the European Position Paper on Rhinosinusitis (EPOS) criteria to study the prevalence of chronic rhinosinusitis (CRS) in a general-population sample. METHODS: A CRS symptom questionnaire was mailed to 23 700 primary care patients from Geisinger Clinic, a health system serving 45 counties in Pennsylvania. CRS cases were categorized into four unique subgroups based on EPOS symptoms: obstruction and discharge with no smell loss or pain/pressure; smell loss without pain/pressure; facial pain and/or pressure without smell loss; and both smell loss and pain/pressure. All cases were required to have nasal obstruction or discharge. Logistic regression was used to evaluate potential factors associated with CRS subgroups. RESULTS: We found that 11.9% of patients met criteria for CRS. Prevalence peaked at 15.9% between ages 50 and 59 years and then dropped to 6.8% after age 69. The odds of CRS was higher among patients who were white, younger, smokers, had a history of Medical Assistance, and had other diseases. When CRS subgroups were modeled separately, these associations were no longer significant for some CRS subgroups. Comorbid diseases were most strongly associated with CRS cases who reported smell loss and facial pain and/or pressure and had the weakest associations with CRS cases who did not report these symptoms. CONCLUSIONS: CRS is a highly prevalent and heterogeneous condition. Differences in risk factors and health outcomes across symptom subgroups may be indicative of differences in etiology that have implications for disease management.
BACKGROUND: The objective of this study was to describe the first US-based study to use the European Position Paper on Rhinosinusitis (EPOS) criteria to study the prevalence of chronic rhinosinusitis (CRS) in a general-population sample. METHODS: A CRS symptom questionnaire was mailed to 23 700 primary care patients from Geisinger Clinic, a health system serving 45 counties in Pennsylvania. CRS cases were categorized into four unique subgroups based on EPOS symptoms: obstruction and discharge with no smell loss or pain/pressure; smell loss without pain/pressure; facial pain and/or pressure without smell loss; and both smell loss and pain/pressure. All cases were required to have nasal obstruction or discharge. Logistic regression was used to evaluate potential factors associated with CRS subgroups. RESULTS: We found that 11.9% of patients met criteria for CRS. Prevalence peaked at 15.9% between ages 50 and 59 years and then dropped to 6.8% after age 69. The odds of CRS was higher among patients who were white, younger, smokers, had a history of Medical Assistance, and had other diseases. When CRS subgroups were modeled separately, these associations were no longer significant for some CRS subgroups. Comorbid diseases were most strongly associated with CRS cases who reported smell loss and facial pain and/or pressure and had the weakest associations with CRS cases who did not report these symptoms. CONCLUSIONS:CRS is a highly prevalent and heterogeneous condition. Differences in risk factors and health outcomes across symptom subgroups may be indicative of differences in etiology that have implications for disease management.
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinology Date: 2012-03 Impact factor: 3.681
Authors: Katherine K Nishimura; Joshua M Galanter; Lindsey A Roth; Sam S Oh; Neeta Thakur; Elizabeth A Nguyen; Shannon Thyne; Harold J Farber; Denise Serebrisky; Rajesh Kumar; Emerita Brigino-Buenaventura; Adam Davis; Michael A LeNoir; Kelley Meade; William Rodriguez-Cintron; Pedro C Avila; Luisa N Borrell; Kirsten Bibbins-Domingo; Jose R Rodriguez-Santana; Śaunak Sen; Fred Lurmann; John R Balmes; Esteban G Burchard Journal: Am J Respir Crit Care Med Date: 2013-08-01 Impact factor: 21.405
Authors: Christopher John Staniorski; Caroline P E Price; Ava R Weibman; Kevin C Welch; David B Conley; Stephanie Shintani-Smith; Whitney W Stevens; Anju T Peters; Leslie Grammer; Alcina K Lidder; Robert P Schleimer; Robert C Kern; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2018-01-05 Impact factor: 3.858
Authors: Agnes S Sundaresan; Annemarie G Hirsch; Amanda J Young; Jonathan Pollak; Bruce K Tan; Robert P Schleimer; Robert C Kern; Thomas L Kennedy; J Scott Greene; Walter F Stewart; Karen Bandeen-Roche; Brian S Schwartz Journal: J Allergy Clin Immunol Pract Date: 2017-11-10
Authors: Sarah-Grace Glennon; Tania Huedo-Medina; Shristi Rawal; Howard J Hoffman; Mark D Litt; Valerie B Duffy Journal: Nicotine Tob Res Date: 2019-05-21 Impact factor: 4.244
Authors: Jordan R Kuiper; Annemarie G Hirsch; Karen Bandeen-Roche; Agnes S Sundaresan; Bruce K Tan; Robert C Kern; Robert P Schleimer; Brian S Schwartz Journal: J Occup Environ Med Date: 2019-08 Impact factor: 2.162
Authors: Ava R Weibman; Julia He Huang; Whitney W Stevens; Lydia A Suh; Caroline P E Price; Alcina K Lidder; David B Conley; Kevin C Welch; Stephanie Shintani-Smith; Anju T Peters; Leslie C Grammer; Atsushi Kato; Robert C Kern; Robert P Schleimer; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2017-09-01 Impact factor: 3.858
Authors: M Cole; K Bandeen-Roche; A G Hirsch; J R Kuiper; A S Sundaresan; B K Tan; R P Schleimer; R C Kern; B S Schwartz Journal: Allergy Date: 2018-05-21 Impact factor: 13.146
Authors: J R Kuiper; A G Hirsch; K Bandeen-Roche; A S Sundaresan; B K Tan; R P Schleimer; R C Kern; W F Stewart; B S Schwartz Journal: Allergy Date: 2018-02-07 Impact factor: 13.146
Authors: Joan A Casey; Jonathan Pollak; M Maria Glymour; Elizabeth R Mayeda; Annemarie G Hirsch; Brian S Schwartz Journal: Am J Prev Med Date: 2017-12-11 Impact factor: 5.043
Authors: Annemarie G Hirsch; Cara Nordberg; Karen Bandeen-Roche; Bruce K Tan; Robert P Schleimer; Robert C Kern; Agnes Sundaresan; Jayant M Pinto; Thomas L Kennedy; Joseph Scott Greene; Jordan R Kuiper; Brian S Schwartz Journal: Allergy Date: 2019-12-02 Impact factor: 13.146